Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Metformin/pioglitazone (Primary)
- Indications Orofacial cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 13 Jul 2017 Planned End Date changed from 31 Mar 2019 to 10 Jun 2019.
- 13 Jul 2017 Planned primary completion date changed from 31 Mar 2019 to 10 Jun 2019.